IMEXHS Limited (ASX: IME) reported first-half FY26 revenue of A$16.0 million, up 17% year on year, while underlying EBITDA increased 311% to A$1.27 million as its radiology-services operation recovered and its cloud medical-imaging platform continued expanding. Annual recurring revenue reached A$36.8 million, up 12% on a reported basis, while the company has guided to FY26 revenue of A$31.4 million to A$33.7 million and underlying EBITDA of A$2.4 million to A$2.7 million.
The September 2 results presentation sharpened the forward picture by showing approximately A$4.4 million of contracted annual recurring revenue that had not yet begun billing. Around A$2.3 million of that amount relates to software, while new radiology contracts including Sanitas and Colsanitas contribute another roughly A$2 million of annual recurring revenue as they commence during Q3.
IME shares had closed at A$0.35 on August 28 and remained at A$0.35 on September 1, leaving the company with a market capitalisation of roughly A$19 million. The muted trading response after the original August 28 results means the investment debate remains centred less on one-day price action and more on whether recently contracted revenue translates into stronger billing, cash collection and recurring profitability.
How much did IMEXHS improve its first-half operating margin?
Underlying EBITDA of A$1.27 million on A$16 million of revenue implies a margin of approximately 7.9%. Using the 311% growth rate, the prior-year underlying EBITDA base was only around A$309,000, while prior-period revenue was approximately A$13.7 million. That implies an EBITDA margin near 2.3% in the comparative half, meaning IMEXHS improved its underlying margin by roughly 5.6 percentage points.
The improvement was driven disproportionately by radiology services. RIMAB revenue increased 24% to A$11.2 million and underlying EBITDA rose from around A$0.3 million to A$1.1 million. Software generated the balance of group revenue, while the new Aquila+ platform is intended to shift more of that business toward AI-enabled workflow automation and higher-value recurring contracts.
That operating leverage matters because IMEXHS is still a very small listed company. A few million dollars of additional recurring revenue can materially alter EBITDA when the technology platform and corporate cost base are already established. The opposite also applies, with delayed billing or slower collections capable of having an outsized effect on cash generation.
Does FY26 guidance require another major earnings acceleration in the second half?
Not necessarily. The A$31.4 million to A$33.7 million revenue guidance implies second-half revenue of approximately A$15.4 million to A$17.7 million after subtracting the A$16 million generated in H1. At the midpoint, IMEXHS needs roughly A$16.55 million of H2 revenue, only modestly above the first-half level.
The EBITDA hurdle is similarly achievable on paper. Full-year guidance of A$2.4 million to A$2.7 million implies H2 underlying EBITDA of around A$1.13 million to A$1.43 million after the A$1.27 million first-half result. The midpoint requirement of approximately A$1.28 million is almost identical to H1.
That makes conversion rather than sheer growth the critical execution variable. IMEXHS does not need to double again in H2 to reach guidance, but it does need contracted software and radiology activity to begin billing broadly on schedule while protecting margins and collecting receivables in Colombia.
Why is the A$4.4 million contracted but unbilled book so important?
The A$4.4 million contracted annual recurring revenue awaiting billing represents about 12% of IMEXHS’ reported A$36.8 million ARR base. It is also equivalent to approximately 23% of the company’s recent A$19 million equity value, although ARR and market capitalisation are different measures and that comparison should be interpreted only as an indication of materiality.
The largest individual software component is associated with Sanitas, while the Sanitas and Colsanitas radiology contracts are expected to add approximately A$2 million of ARR when operational. IMEXHS expects about A$1.2 million of contracted software ARR to begin billing by the end of Q3.
The backlog therefore provides much stronger visibility than an uncontracted sales pipeline. It is already signed business progressing through implementation, although implementation timing can still move and contracted ARR does not necessarily translate dollar-for-dollar into revenue in the same accounting period.
Management has also acknowledged that new software ARR remains uneven, with recent performance relying partly on larger episodic wins rather than a consistently repeatable stream of mid-sized transactions. The Zacatecas public-health tender in Mexico demonstrated that IMEXHS can win large institutional deployments, but the commercial model becomes more durable only when similar wins occur across multiple territories.
What does Aquila+ change about the IMEXHS business model?
Aquila+ is IMEXHS’ agentic AI platform for radiology workflow automation. Two proprietary agents are already live across the customer base, another two have completed development and four more are in testing or active development. The agents are owned by IMEXHS rather than licensed from a third party, giving the company control over pricing and commercial deployment.
The strategic advantage is that IMEXHS also operates the RIMAB radiology-services business. That gives the software team a real clinical environment in which to test workflow automation against actual reporting volumes and operating costs before wider external deployment.
The Mexico deployment provides an early external proof point. IMEXHS won a public tender in Zacatecas covering 20 hospitals and clinics and contributing approximately A$384,000 of new software ARR, with five proprietary workflow agents and two third-party diagnostic algorithms included in the deployment.
If Aquila+ can automate scheduling, workflow prioritisation and reporting tasks while improving turnaround times, the economic opportunity could appear in two places: higher software ARR from external customers and improved margins inside IMEXHS’ own radiology-services operation.
Why does cash collection remain a bigger risk than debt?
IMEXHS held approximately A$2 million of cash at June 30 and only A$250,000 of debt, meaning leverage itself is not the principal balance-sheet concern. Cash nevertheless fell from A$3.3 million at December 31, and operating activities consumed approximately A$400,000 during H1.
The bigger issue is collection timing within Colombia’s healthcare system. Management has highlighted payment delays linked to government funding of health insurers, and improved political or economic sentiment does not automatically translate into faster cash receipts.
That leaves IMEXHS with an unusual H2 setup. Guidance does not require dramatic additional EBITDA acceleration, and the company already has meaningful contracted revenue waiting to commence billing. What it does require is execution discipline around implementation and receivables.
If IMEXHS converts the A$4.4 million contracted-but-not-billing book while maintaining the first-half margin improvement, the company could enter FY27 with a materially stronger recurring-revenue and earnings base. If implementation or collections slip, the A$2 million cash position gives management far less room for error than the A$36.8 million ARR headline might imply.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
